Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Primary Myelofibrosis 4Myeloproliferative Disorders 4Carcinoma, Non-Small-Cell Lung 4Hematologic Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Hodgkin Disease 2Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Inhibition, Psychological 1Histiocytoma, Malignant Fibrous 1Hematologic Diseases 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × INCB039110 × Clear all
NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 1/2 Completed
59 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡